Long-term Evaluation After Topical Cyclosporine Treatment in Dry Eye Patients With Graft-Versus-Host Disease.
10.3341/jkos.2009.50.1.27
- Author:
Seung Hyun LEE
1
;
Seoung Kyu IM
;
Je Moon WOO
;
Kyung Chul YOON
Author Information
1. Department of Ophthalmology, Chonnam National University Medical School, Gwangju, Korea. kcyoon@chonnam.ac.kr
- Publication Type:Original Article
- Keywords:
Cyclosporine;
Dry eye syndrome;
Graft-versus-host disease
- MeSH:
Cyclosporine;
Dry Eye Syndromes;
Eye;
Graft vs Host Disease;
Humans;
Tears
- From:Journal of the Korean Ophthalmological Society
2009;50(1):27-33
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was performed to evaluate the long-term effect of 0.05% cyclosporine A emulsion (Restasis, Allergan Inc. USA.) on dry eye associated with graft-versus-host disease (GVHD). METHODS: Sixteen eyes of 8 patients with severe dry eye associated with GVHD were treated with 0.05% cyclosporine A emulsion twice a day. Tear film parameters were evaluated before treatment and after 1, 3, 6, and 12 months of treatment. RESULTS: One month after treatment, tear break-up time improved from 3.88+/-1.78 s to 4.17+/-1.90 s (P=0.02). Three months after treatment, symptom score and basal secretion improved from 3.00+/-0.38 and 4.44+/-1.59 mm to 2.33+/-0.52 (P=0.04) and 5.42+/-2.50 mm (P=0.04), respectively. Twelve months after treatment, the keratoepitheliopathy score improved from 2.38+/-1.31 to 1.13+/-0.35 (P=0.02). CONCLUSIONS: Use of a 0.05% cyclosporine A emulsion is effective for dry eye associated with GVHD as it helps to increase tear secretion and to relieve symptoms. Treatment with 0.05% cyclosporine A emulsion for longer than 1 year may be necessary to improve keratoepitheliopathy.
